glp 1 medicaid coverage 📢 New Resource Alert! We've added an important update to our Resource Library: Changes to GLP‑1 under Pennsylvania If you or someone you support uses GLP‑1 medications and you are Does health insurance cover GLP-1

Description

A reporting summary for this Article is available as a Supplementary Information file

Highlights: Nearly 40% of patients stopped GLP-1 therapy within the first year More than half of those who stopped later restarted treatment Side effects, cost, and access barriers were common reasons for treatment interruptions Reduce appetite Improve blood sugar control Promote weight loss Lower the risk of certain cardiovascular complications Trusted Source Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity Go to source)

Understanding both the direct and indirect factors contributing to fatigue helps guide appropriate management strategies and medication adjustments when necessary

p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis